Onoclogy Software Designed for Drug Discovery, Biomarker Research
By LabMedica International staff writers
Posted on 07 May 2012
A new software application quantitatively measures 130 cancer-related proteins that can help researchers hasten the pace of discovery and validation of cancer-related biomarkers for early detection, patient stratification, and therapeutic monitoring. Posted on 07 May 2012
OncologyMAP v2.0 is a powerful tool developed with guidance and funding from the US National Cancer Institute (NCI; Bethesda, MD, USA) and the Cancer Prevention and Research Institute of Texas (CPRIT; Austin, USA). The software is validated to clinical laboratory standards, allowing discoveries made during the basic research stages to be effectively extended into clinical trials. The use of these sensitive and reproducible biomarkers as objective gauges of disease progression, drug efficacy, and toxicity can facilitate decision-making and help avoid the high costs linked with late-stage drug attrition.
OncologyMAP v2.0 is based on Myriad RBM’s (Austin, TX, USA) proprietary multianalyte profiling (MAP) platform, which quantifies blood-based biomarkers representing dozens of important biologic pathways. The multiplexing process increases efficiency and provides excellent accuracy and precision.
Related Links:
Myriad RBM